Get the Stockscreener App
0.9865
8.89%
0.0805
After Hours:
.94
-0.0465
-4.71%
Promis Neurosciences Inc stock is traded at $0.9865, with a volume of 4.92M.
It is up +8.89% in the last 24 hours and up +103.40% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.906
Open:
$0.9
24h Volume:
4.92M
Relative Volume:
0.78
Market Cap:
$32.25M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-4.9424
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+124.15%
1M Performance:
+103.40%
6M Performance:
+10.37%
1Y Performance:
-51.11%
1-Day Range:
$0.8746
$1.06
1-Week Range:
$0.77
$1.59
52-Week Range:
$0.38
$2.05
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.9865 | 29.62M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Stock (PMN) Latest News
What drives ProMIS Neurosciences Inc. stock priceMassive portfolio appreciation - PrintWeekIndia
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
ProMIS Neurosciences Alights on Path to Novel Alzheimer’s Treatment - StocksToTrade
ProMIS Neurosciences Inc. Stock Analysis and ForecastExplosive earnings growth - Autocar Professional
What analysts say about ProMIS Neurosciences Inc. stockAccelerated earnings growth - PrintWeekIndia
When is the best time to buy ProMIS Neurosciences Inc. stockHigh-impact stock picks - jammulinksnews.com
Is ProMIS Neurosciences Inc. stock a growth or value playFree Predictions - jammulinksnews.com
Will ProMIS Neurosciences Inc. stock split in the near futureConsistent triple-digit returns - jammulinksnews.com
ProMIS Neurosciences Gains FDA Fast Track for PMN310 - The Globe and Mail
Is ProMIS Neurosciences Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
ProMIS Neurosciences Announces $3.2M Fundraising Initiatives - TipRanks
Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede - Cantech Letter
Alzheimer’s stock triples after FDA Fast-Track Designation - MSN
ProMIS Neurosciences Plunges 24.56% Intraday—Is the FDA Fast Track Outpacing Investor Sentiment? - AInvest
ProMIS Neurosciences Plunges 28% Intraday—Is This the Catalyst No One Saw Coming? - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyBreakout Level Watch - Newser
Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential - TipRanks
ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire
ProMIS Neurosciences announces $0.8M registered direct offering - TipRanks
ProMIS Neurosciences announces private placement financing - TipRanks
ProMIS Neurosciences stock gets FDA Fast Track designation for PMN310 - Investing.com
ProMIS Neurosciences (PMN) Secures Funding to Enhance Therapeuti - GuruFocus
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times
ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus
ProMIS Neurosciences Announces $2.4 Million PIPE Financing for Clinical Development of PMN310 - Nasdaq
ProMIS Neurosciences Drops 9.82% Amid ICICI Bank's Strong Earnings - AInvest
ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia
3 Penny Stocks to Watch Now, 7/22/25 - TipRanks
ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com
ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail
Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse
ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest
ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest
Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest
ProMIS Neurosciences: Stock Surge Insight - StocksToTrade
ProMIS Neurosciences Soars 157% on FDA Fast Track Designation – What’s Fueling This Volatile Rally? - AInvest
ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com
ProMIS Neurosciences Surges: Analyzing Recent Moves - timothysykes.com
ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks
ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):